All In Biotech

Drug Trial Radar · NCT01496313

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

Jun 8, 2012

Primary completion

Apr 2, 2014

Study completion Jul 11, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.

Conditions

  • Thyroid Cancer

Interventions

  • 300mg vandetanibDrug

    Oral blinded tablets taken once daily. At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment Dosing with unblinded study treatment can continue until 24 months after patient was randomised. At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.

  • 150mg vandetanibDrug

    Oral blinded tablets taken once daily. At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg Dosing with unblinded study treatment can continue until 24 months after patient was randomised At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the InvestigatorTime frame: Randomisation to week 60 (maximum)

Locations

30 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Houston, Texas

  • Investigational Site Number : 1903

    Olomouc, Czechia

  • Research Site

    Olomouc, Czechia

  • Investigational Site Number : 1901

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Bangalore Karnataka, India

  • Research Site

    Vellore, India

  • Research Site

    Beersheba, Israel

  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Catania, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Palermo, Italy

  • Research Site

    Pisa, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Siena, Italy

  • Research Site

    Torino, Italy

  • Research Site

    Groningen, Netherlands

  • Research Site

    Leiden, Netherlands

  • Investigational Site Number : 5703

    Gliwice, Poland

  • Research Site

    Gliwice, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Zgierz, Poland

  • Investigational Site Number : 5704

    Warsaw, Masovian Voivodeship, Poland

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Cardiff, United Kingdom

  • Research Site

    Greater London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Tyne & Wear, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.